Home - Bioporto
2024年11月22日 · BioPorto is dedicated to providing clinicians with tools to make impactful changes in patient management; currently, the NGAL biomarker to aid in the risk assessment and diagnosis of acute kidney injury. Rapidly detect acute kidney injury with The NGAL Test™.
Home - BioPorto US
2024年11月22日 · Stay up to date with the latest resources for kidney care, and news about BioPorto.
About BioPorto - Bioporto
2024年4月12日 · BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management.
NGAL - Bioporto
2024年6月7日 · support the use of NGAL as a safety biomarker for early identification of renal toxicity. BioPorto’s NGAL ELISA kits are available in six species – the bridge from pre-clinical research to clinical trials. Stay up to date with the latest resources for kidney care, and news about BioPorto.
News - BioPorto US
2024年4月4日 · BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States. ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker cleared for pediatric use (aged 3 months through 21 years) in the US and is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI. Read More
BioPorto A/S - LinkedIn
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient...
New trial design paved the way for Bioporto's crucial FDA
2023年12月8日 · Bioporto changed the clinical trial design for its kidney test, which is why the company finally got FDA approval after 10 years of effort, says Antony Pare, CEO since 2021.
Products - Bioporto
2024年6月12日 · We provide tests and antibodies to clinicians and researchers around the world, leveraging our expertise to transform novel research tools into clinically actionable biomarkers designed to make a difference in patients’ lives. Showing 1 to 10 of 150 total.
NGAL - BioPorto US
2024年7月22日 · BioPorto’s NGAL ELISA kits are available in six species – the bridge from pre-clinical research to clinical trials. BioPorto’s NGAL products are marketed under applicable registrations in several countries worldwide. Learn about our clinical and research products outside the US by visiting our global site.
BioPorto A/S (CPH: BIOPOR) Company Profile & Overview - Stock …
2024年11月15日 · BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally.
Company News - Bioporto
2024年11月5日 · BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States. ProNephro AKI (NGAL) is the first Acute Kidney Injury (AKI) biomarker cleared for pediatric use (aged 3 months through 21 years) in the US and is designed to help doctors identify patients at risk of developing or having persistent, moderate-to-severe AKI. Read More
BioPorto commences process to appoint new Chair of the
4 天之前 · December 16, 2024. Announcement no. 23. BioPorto commences process to appoint new Chair of the Board of Directors COPENHAGEN, DENMARK, December 16, 2024 (GLOBE NEWSWIRE) – The Board of Directors ...
Customer Care - BioPorto US
We are dedicated to helping care teams improve treatment plans and patient outcomes. Supporting our customers and the patients who depend on them is at the heart of our business. Visit FAQs to find answers to common questions. Contact us for assistance including technical documents. Ready to Order? We are happy to help. Still Have Questions?
Investor Relations - Bioporto
2019年9月20日 · BioPorto is listed on the NASDAQ Copenhagen stock exchange. View BioPorto newswire announcements. Recent investor presentations. View BioPorto Annual Reports. …
BioPorto (BIOPOR) aktie - Nordnet
Køb BioPorto (BIOPOR) aktien. Hos Nordnet kan du handle fra 0 kr. i kurtage. Klik her for at følge aktiekursen i realtid
Careers - Bioporto
2024年11月21日 · We are passionate about improving health by providing innovative diagnostic and research tools. Join Our Team! If you enjoy working in an agile, mission-driven company that is focused on launching novel biomarker tests designed to help improve patient outcomes, we’d like to hear from you.
Careers - BioPorto US
2024年10月15日 · BioPorto is an agile, mission-driven company focused on launching novel biomarker tests designed to help improve patient outcomes. Careers at BioPorto - join a passionate team focused on improving health by providing …
- 某些结果已被删除一些您可能无法访问的结果已被隐去。显示无法访问的结果